The present invention relates to a family of very stable aqueous hypochlorite products and methods for reducing the self reactivity of Ca(OCl).sub.2.

The present invention relates to a family of very stable aqueous hypochlorite products and methods for reducing the self reactivity of Ca(OCl).sub.2.

Stable S-(+)-abscisic acid (S-ABA) non-aqueous liquid solutions are generally achieved without the use of an effective amount of an antioxidant and/or an ultraviolet absorber to S-(+)-abscisic acid. In a preferred embodiment, the stable S-(+)-abscisic acid (S-ABA) nonaqueous liquid solutions includes at least one organic solvent, such as at least one polyethylene glycol, at least one glycol, and/or at least one lactamide and/or at least one pentanoate.

Stable S-(+)-abscisic acid (S-ABA) non-aqueous liquid solutions are generally achieved without the use of an effective amount of an antioxidant and/or an ultraviolet absorber to S-(+)-abscisic acid. In a preferred embodiment, the stable S-(+)-abscisic acid (S-ABA) nonaqueous liquid solutions includes at least one organic solvent, such as at least one polyethylene glycol, at least one glycol, and/or at least one lactamide and/or at least one pentanoate.

Compositions for providing stability to RNA may include a primary surfactant, and a metal-ion sequestrant. The primary surfactant may be a nonionic surfactant. The composition may be in a soluble liquid concentrate form and may be sufficient to provide shelf stability to RNA for one year at room temperature. Compositions for delivering RNA to a pest via exogenous, foliar application of the composition to a plant may comprise RNA; a primary surfactant; and a metal-ion sequestrant.

Compositions for providing stability to RNA may include a primary surfactant, and a metal-ion sequestrant. The primary surfactant may be a nonionic surfactant. The composition may be in a soluble liquid concentrate form and may be sufficient to provide shelf stability to RNA for one year at room temperature. Compositions for delivering RNA to a pest via exogenous, foliar application of the composition to a plant may comprise RNA; a primary surfactant; and a metal-ion sequestrant.

An antimicrobial solution for a medical device having a chamber defined by a wall, the chamber being configured to be includes water, and an amount of iodine in the water sufficient to generate free elemental iodine when introduced into the chamber of the medical device. The free elemental iodine is configured to diffuse through the wall of the chamber and/or be embedded in the wall of the chamber of the medical device to form an antimicrobial polymer on the wall of the chamber.

An antimicrobial solution for a medical device having a chamber defined by a wall, the chamber being configured to be includes water, and an amount of iodine in the water sufficient to generate free elemental iodine when introduced into the chamber of the medical device. The free elemental iodine is configured to diffuse through the wall of the chamber and/or be embedded in the wall of the chamber of the medical device to form an antimicrobial polymer on the wall of the chamber.

A light stable, environmentally friendly, broad spectrum antimicrobial disinfectants comprising of active metal ions and method of preparing the same are provided. The compositions are non-toxic, cost-effective formulations, comprising of metal ions, biopolymer, and complexing agent. The compositions are very effective with the dosing and treatment regime designed to give a 6-log reduction in bacteria and virus count and also expected to yield 30 days or more of residual efficacy.

A light stable, environmentally friendly, broad spectrum antimicrobial disinfectants comprising of active metal ions and method of preparing the same are provided. The compositions are non-toxic, cost-effective formulations, comprising of metal ions, biopolymer, and complexing agent. The compositions are very effective with the dosing and treatment regime designed to give a 6-log reduction in bacteria and virus count and also expected to yield 30 days or more of residual efficacy.